GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (FRA:8EM) » Definitions » Operating Margin %

Editas Medicine (FRA:8EM) Operating Margin % : -107,572.73% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Editas Medicine's Operating Income for the three months ended in Sep. 2024 was €-59.17 Mil. Editas Medicine's Revenue for the three months ended in Sep. 2024 was €0.06 Mil. Therefore, Editas Medicine's Operating Margin % for the quarter that ended in Sep. 2024 was -107,572.73%.

Warning Sign:

Editas Medicine Inc operating margin has been in a 5-year decline. The average rate of decline per year is -2%.

The historical rank and industry rank for Editas Medicine's Operating Margin % or its related term are showing as below:

FRA:8EM' s Operating Margin % Range Over the Past 10 Years
Min: -2167.71   Med: -756.13   Max: -148.61
Current: -370.03


FRA:8EM's Operating Margin % is ranked worse than
61.62% of 1011 companies
in the Biotechnology industry
Industry Median: -162.31 vs FRA:8EM: -370.03

Editas Medicine's 5-Year Average Operating Margin % Growth Rate was -2.00% per year.

Editas Medicine's Operating Income for the three months ended in Sep. 2024 was €-59.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was €-209.57 Mil.


Editas Medicine Operating Margin % Historical Data

The historical data trend for Editas Medicine's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Operating Margin % Chart

Editas Medicine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -686.38 -148.61 -756.14 -1,146.27 -216.56

Editas Medicine Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -940.06 -39.90 -5,903.45 -14,003.77 -107,572.73

Competitive Comparison of Editas Medicine's Operating Margin %

For the Biotechnology subindustry, Editas Medicine's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Operating Margin % falls into.



Editas Medicine Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Editas Medicine's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-155.139 / 71.639
=-216.56 %

Editas Medicine's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=-59.165 / 0.055
=-107,572.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Editas Medicine  (FRA:8EM) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Editas Medicine Operating Margin % Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines